ALXO
ALX Oncology Holdings Inc.
Price Chart
Latest Quote
$1.68
Current Price| Previous Close | $1.74 |
| Open | $1.66 |
| Day High | $1.81 |
| Day Low | $1.65 |
| Volume | 250,498 |
Stock Information
| Shares Outstanding | 54.22M |
| Total Debt | $15.61M |
| Cash Equivalents | $60.63M |
| Net Income | $-108.01M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $91.09M |
| EPS (TTM) | $-2.01 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 17/42| Debt to Equity | 0.09 |
| Debt to Earnings | -0.07 |
| Current Ratio | 7.26 |
| Quick Ratio | 6.91 |
| Return on Equity | -118.69% |
| Avg FCF Growth | 16.89% |
| FCF Yield | -134.33% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $1.68 | 250,800 |
| 2026-01-30 | $1.74 | 2,238,200 |
| 2026-01-29 | $1.57 | 550,600 |
| 2026-01-28 | $1.37 | 110,500 |
| 2026-01-27 | $1.50 | 130,400 |
| 2026-01-26 | $1.48 | 103,900 |
| 2026-01-23 | $1.40 | 85,600 |
| 2026-01-22 | $1.47 | 252,800 |
| 2026-01-21 | $1.47 | 254,200 |
| 2026-01-20 | $1.32 | 280,200 |
| 2026-01-16 | $1.17 | 204,500 |
| 2026-01-15 | $1.21 | 241,600 |
| 2026-01-14 | $1.33 | 282,400 |
| 2026-01-13 | $1.49 | 198,400 |
| 2026-01-12 | $1.44 | 243,300 |
| 2026-01-09 | $1.35 | 277,400 |
| 2026-01-08 | $1.24 | 312,600 |
| 2026-01-07 | $1.18 | 164,700 |
| 2026-01-06 | $1.08 | 220,200 |
| 2026-01-05 | $1.12 | 690,200 |
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
📰 Latest News
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference
MarketBeat • 2026-01-15T22:17:02Z
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks
Simply Wall St. • 2026-01-12T18:05:30Z
ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ...
GuruFocus.com • 2025-11-08T07:05:05Z
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?
Zacks • 2025-10-14T13:40:02Z
3 Promising Penny Stocks With Market Caps Under $700M
Simply Wall St. • 2025-09-25T18:05:26Z
CEO & Director of ALX Oncology Holdings Picks Up 69% More Stock
Simply Wall St. • 2025-09-21T12:39:08Z
3 Promising Penny Stocks With Market Caps Over $40M
Simply Wall St. • 2025-08-22T12:08:40Z
ALX Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Highlights: Promising Trial Results and ...
GuruFocus.com • 2025-08-13T07:13:44Z
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials
Clinical Trials Arena • 2025-04-28T11:51:13Z
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks • 2025-03-20T13:55:03Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | $0 | $0 |
| Cost Of Revenue | - | - | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $1,729,000 | $1,565,000 | $238,000 | $13,000 |
| Total Expenses | $142,467,000 | $170,278,000 | $127,436,000 | $83,555,000 |
| Other Income Expense | $-20,000 | $389,000 | $-22,000 | $-7,000 |
| Other Non Operating Income Expenses | $-20,000 | $389,000 | $-22,000 | $-7,000 |
| Net Non Operating Interest Income Expense | $7,637,000 | $9,084,000 | $4,040,000 | $78,000 |
| Interest Expense Non Operating | $1,729,000 | $1,565,000 | $238,000 | $13,000 |
| Operating Expense | $142,467,000 | $170,278,000 | $127,436,000 | $83,555,000 |
| General And Administrative Expense | $26,094,000 | $28,483,000 | $29,036,000 | $23,385,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-134,850,000 | $-160,805,000 | $-123,482,000 | $-83,463,000 |
| Net Interest Income | $7,637,000 | $9,084,000 | $4,040,000 | $78,000 |
| Interest Income | $9,366,000 | $10,649,000 | $4,278,000 | $91,000 |
| Normalized Income | $-134,850,000 | $-160,805,000 | $-123,482,000 | $-83,463,000 |
| Net Income From Continuing And Discontinued Operation | $-134,850,000 | $-160,805,000 | $-123,482,000 | $-83,463,000 |
| Total Operating Income As Reported | $-142,467,000 | $-170,278,000 | $-127,436,000 | $-83,555,000 |
| Net Income Common Stockholders | $-134,850,000 | $-160,805,000 | $-123,482,000 | $-83,463,000 |
| Net Income | $-134,850,000 | $-160,805,000 | $-123,482,000 | $-83,463,000 |
| Net Income Including Noncontrolling Interests | $-134,850,000 | $-160,805,000 | $-123,482,000 | $-83,463,000 |
| Net Income Continuous Operations | $-134,850,000 | $-160,805,000 | $-123,482,000 | $-83,463,000 |
| Pretax Income | $-134,850,000 | $-160,805,000 | $-123,418,000 | $-83,484,000 |
| Interest Income Non Operating | $9,366,000 | $10,649,000 | $4,278,000 | $91,000 |
| Operating Income | $-142,467,000 | $-170,278,000 | $-127,436,000 | $-83,555,000 |
| Special Income Charges | - | - | $0 | $0 |
| Gross Profit | - | - | $0 | $0 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-2.58 | $-3.74 | $-3.03 | $-2.07 |
| Basic EPS | $-2.58 | $-3.74 | $-3.03 | $-2.07 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-132,249,000 | $-158,404,000 | $-122,838,000 | $-83,420,000 |
| Reconciled Depreciation | $872,000 | $836,000 | $342,000 | $51,000 |
| EBITDA (Bullshit earnings) | $-132,249,000 | $-158,404,000 | $-122,838,000 | $-83,420,000 |
| EBIT | $-133,121,000 | $-159,240,000 | $-123,180,000 | $-83,471,000 |
| Diluted Average Shares | $52,174,904 | $42,987,767 | $40,699,612 | $40,308,050 |
| Basic Average Shares | $52,174,904 | $42,987,767 | $40,699,612 | $40,308,050 |
| Diluted NI Availto Com Stockholders | $-134,850,000 | $-160,805,000 | $-123,482,000 | $-83,463,000 |
| Tax Provision | $0 | $0 | $64,000 | $-21,000 |
| Research And Development | $116,373,000 | $141,795,000 | $98,400,000 | $60,170,000 |
| Selling General And Administration | $26,094,000 | $28,483,000 | $29,036,000 | $23,385,000 |
| Other Gand A | $9,872,000 | $9,775,000 | $10,171,000 | $23,385,000 |
| Salaries And Wages | $16,222,000 | $18,708,000 | $18,865,000 | $14,050,000 |
| Total Unusual Items | - | - | $0 | $0 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $113,618,000 | $189,712,000 | $263,464,000 | $363,049,000 |
| Total Assets | $147,775,000 | $242,553,000 | $306,489,000 | $380,183,000 |
| Total Non Current Assets | $13,423,000 | $53,894,000 | $35,520,000 | $13,164,000 |
| Other Non Current Assets | $200,000 | $200,000 | $288,000 | - |
| Non Current Prepaid Assets | $67,000 | $7,442,000 | $8,720,000 | $9,692,000 |
| Investmentin Financial Assets | $3,524,000 | $35,411,000 | $16,699,000 | $0 |
| Current Assets | $134,352,000 | $188,659,000 | $270,969,000 | $367,019,000 |
| Other Current Assets | $6,595,000 | $5,923,000 | $4,762,000 | $3,352,000 |
| Cash Cash Equivalents And Short Term Investments | $127,757,000 | $182,736,000 | $266,207,000 | $363,667,000 |
| Cash And Cash Equivalents | $17,567,000 | $22,406,000 | $48,822,000 | $363,667,000 |
| Non Current Accounts Receivable | - | - | $78,000 | - |
| Prepaid Assets | - | - | - | $3,352,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $9,904,000 | $9,639,000 | $9,389,000 | $742,000 |
| Long Term Debt And Capital Lease Obligation | $9,469,000 | $9,639,000 | $9,389,000 | - |
| Long Term Debt | $9,469,000 | $9,639,000 | $9,389,000 | - |
| Current Debt And Capital Lease Obligation | $435,000 | $1,575,000 | $1,041,000 | $742,000 |
| Current Debt | $435,000 | - | - | - |
| Other Current Borrowings | $435,000 | - | - | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $34,157,000 | $52,841,000 | $43,025,000 | $17,134,000 |
| Total Non Current Liabilities Net Minority Interest | $15,657,000 | $16,840,000 | $14,700,000 | $1,839,000 |
| Other Non Current Liabilities | $6,188,000 | $7,201,000 | $5,311,000 | $1,839,000 |
| Current Liabilities | $18,500,000 | $36,001,000 | $28,325,000 | $15,295,000 |
| Other Current Liabilities | $2,573,000 | $2,205,000 | $2,050,000 | $236,000 |
| Payables And Accrued Expenses | $10,186,000 | $27,729,000 | $22,567,000 | $11,023,000 |
| Payables | $4,646,000 | $9,134,000 | $9,723,000 | $5,394,000 |
| Accounts Payable | $4,497,000 | $8,591,000 | $8,073,000 | $3,764,000 |
| Other Payable | - | - | - | $1,630,000 |
| Total Tax Payable | - | - | - | $0 |
| Income Tax Payable | - | - | - | $0 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $113,618,000 | $189,712,000 | $263,464,000 | $363,049,000 |
| Total Equity Gross Minority Interest | $113,618,000 | $189,712,000 | $263,464,000 | $363,049,000 |
| Stockholders Equity | $113,618,000 | $189,712,000 | $263,464,000 | $363,049,000 |
| Gains Losses Not Affecting Retained Earnings | $275,000 | $256,000 | $-845,000 | $0 |
| Other Equity Adjustments | $275,000 | $256,000 | $-845,000 | - |
| Retained Earnings | $-621,122,000 | $-486,272,000 | $-325,467,000 | $-201,985,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $53,052,912 | $49,951,989 | $40,861,386 | $40,587,067 |
| Share Issued | $53,052,912 | $49,951,989 | $40,861,386 | $40,587,067 |
| Tangible Book Value | $113,618,000 | $189,712,000 | $263,464,000 | $363,049,000 |
| Invested Capital | $123,522,000 | $199,351,000 | $272,853,000 | $363,049,000 |
| Working Capital | $115,852,000 | $152,658,000 | $242,644,000 | $351,724,000 |
| Total Capitalization | $123,087,000 | $199,351,000 | $272,853,000 | $363,049,000 |
| Additional Paid In Capital | $734,412,000 | $675,678,000 | $589,735,000 | $564,993,000 |
| Capital Stock | $53,000 | $50,000 | $41,000 | $41,000 |
| Common Stock | $53,000 | $50,000 | $41,000 | $41,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,306,000 | $6,067,000 | $3,708,000 | $3,294,000 |
| Current Accrued Expenses | $5,540,000 | $18,595,000 | $12,844,000 | $5,629,000 |
| Dueto Related Parties Current | $149,000 | $543,000 | $1,650,000 | $1,630,000 |
| Investments And Advances | $3,524,000 | $35,411,000 | $16,699,000 | $0 |
| Available For Sale Securities | $3,524,000 | $35,411,000 | $16,699,000 | - |
| Net PPE | $9,632,000 | $10,841,000 | $9,813,000 | $3,472,000 |
| Accumulated Depreciation | $-2,077,000 | $-1,237,000 | $-403,000 | $-63,000 |
| Gross PPE | $11,709,000 | $12,078,000 | $10,216,000 | $3,535,000 |
| Leases | $2,509,000 | $2,513,000 | $2,360,000 | $229,000 |
| Other Properties | $8,562,000 | $8,985,000 | $7,346,000 | $2,899,000 |
| Machinery Furniture Equipment | $638,000 | $580,000 | $510,000 | $407,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $110,190,000 | $160,330,000 | $217,385,000 | $0 |
| Capital Lease Obligations | - | $7,558,000 | $1,041,000 | $742,000 |
| Long Term Capital Lease Obligation | - | $5,983,000 | - | - |
| Current Capital Lease Obligation | - | $1,575,000 | $1,041,000 | $742,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-122,359,000 | $-131,638,000 | $-90,650,000 | $-73,024,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-121,912,000 | $-130,364,000 | $-89,223,000 | $-68,101,000 |
| Cash Flow From Continuing Operating Activities | $-121,912,000 | $-130,364,000 | $-89,223,000 | $-68,101,000 |
| Operating Gains Losses | $10,000 | - | - | - |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-447,000 | $-1,274,000 | $-1,427,000 | $-4,923,000 |
| Investing Cash Flow | $86,256,000 | $44,657,000 | $-235,416,000 | $-4,923,000 |
| Cash Flow From Continuing Investing Activities | $86,256,000 | $44,657,000 | $-235,416,000 | $-4,923,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $0 | $58,887,000 | $0 | $0 |
| Financing Cash Flow | $30,817,000 | $59,291,000 | $9,860,000 | $2,472,000 |
| Cash Flow From Continuing Financing Activities | $30,817,000 | $59,291,000 | $9,860,000 | $2,472,000 |
| Net Other Financing Charges | $29,661,000 | - | $-655,000 | - |
| Net Common Stock Issuance | $0 | $58,887,000 | $0 | $0 |
| Common Stock Issuance | $0 | $58,887,000 | $0 | $0 |
| Net Preferred Stock Issuance | - | - | $0 | $0 |
| Preferred Stock Issuance | - | - | $0 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-827,000 | $-388,000 | $-388,000 | $-281,000 |
| Issuance Of Debt | $0 | $0 | $10,000,000 | $0 |
| Interest Paid Supplemental Data | $1,387,000 | $1,177,000 | $103,000 | $11,000 |
| End Cash Position | $17,633,000 | $22,472,000 | $48,888,000 | $363,667,000 |
| Beginning Cash Position | $22,472,000 | $48,888,000 | $363,667,000 | $434,219,000 |
| Changes In Cash | $-4,839,000 | $-26,416,000 | $-314,779,000 | $-70,552,000 |
| Proceeds From Stock Option Exercised | $1,983,000 | $792,000 | $903,000 | $2,753,000 |
| Net Issuance Payments Of Debt | $-827,000 | $-388,000 | $9,612,000 | $-281,000 |
| Net Long Term Debt Issuance | $-827,000 | $-388,000 | $9,612,000 | $-281,000 |
| Long Term Debt Payments | $-827,000 | $-388,000 | $-388,000 | $-281,000 |
| Long Term Debt Issuance | $0 | $0 | $10,000,000 | $0 |
| Net Investment Purchase And Sale | $86,703,000 | $45,931,000 | $-233,989,000 | $0 |
| Sale Of Investment | $194,109,000 | $292,560,000 | $142,800,000 | $0 |
| Purchase Of Investment | $-107,406,000 | $-246,629,000 | $-376,789,000 | $0 |
| Net PPE Purchase And Sale | $-447,000 | $-1,274,000 | $-1,427,000 | $-666,000 |
| Purchase Of PPE | $-447,000 | $-1,274,000 | $-1,427,000 | $-666,000 |
| Change In Working Capital | $-12,430,000 | $8,297,000 | $9,850,000 | $-4,027,000 |
| Change In Other Current Liabilities | $-2,071,000 | $-2,353,000 | $-977,000 | $-698,000 |
| Change In Other Current Assets | $7,375,000 | $1,366,000 | $750,000 | $-9,682,000 |
| Change In Payables And Accrued Expense | $-17,042,000 | $10,575,000 | $11,553,000 | $8,015,000 |
| Change In Accrued Expense | $-12,624,000 | $11,224,000 | $7,027,000 | $3,306,000 |
| Change In Payable | $-4,418,000 | $-649,000 | $4,526,000 | $4,709,000 |
| Change In Account Payable | $-4,418,000 | $-649,000 | $4,526,000 | $4,709,000 |
| Change In Prepaid Assets | $-692,000 | $-1,291,000 | $-1,476,000 | $-1,662,000 |
| Other Non Cash Items | $2,050,000 | $1,522,000 | $1,168,000 | $5,424,000 |
| Stock Based Compensation | $27,093,000 | $26,273,000 | $23,839,000 | $13,914,000 |
| Amortization Of Securities | $-4,657,000 | $-6,487,000 | $-940,000 | $0 |
| Depreciation Amortization Depletion | $872,000 | $836,000 | $342,000 | $51,000 |
| Depreciation And Amortization | $872,000 | $836,000 | $342,000 | $51,000 |
| Gain Loss On Sale Of PPE | $10,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $-134,850,000 | $-160,805,000 | $-123,482,000 | $-83,463,000 |
| Income Tax Paid Supplemental Data | - | $0 | $0 | $274,000 |
| Net Intangibles Purchase And Sale | - | $0 | $0 | $-4,257,000 |
| Purchase Of Intangibles | - | $0 | $0 | $-4,257,000 |
| Change In Receivables | - | - | $0 | $0 |